id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-N-5381-0005,FDA,FDA-2024-N-5381,Reference 18 Buprenorphine dosing for the treatment of opioid use disorder,Supporting & Related Material,Background Material,2025-01-06T05:00:00Z,2025,1,,,2025-01-06T19:19:09Z,,0,0,09000064868a01ee
FDA-2024-N-5381-0002,FDA,FDA-2024-N-5381,Reference 15 Evidence on Buprenorphine Dose Limits A Review,Supporting & Related Material,Background Material,2025-01-06T05:00:00Z,2025,1,,,2025-01-06T19:18:56Z,,0,0,09000064868a017e
FDA-2024-N-5381-0004,FDA,FDA-2024-N-5381,Reference 17 The effect of serum from women with antiphospholipid,Supporting & Related Material,Background Material,2025-01-06T05:00:00Z,2025,1,,,2025-01-06T19:19:03Z,,0,0,09000064868a0180
FDA-2024-N-5381-0003,FDA,FDA-2024-N-5381,Reference 16 Thematic Analysis of State Medicaid Buprenorphine,Supporting & Related Material,Background Material,2025-01-06T05:00:00Z,2025,1,,,2025-01-06T19:18:59Z,,0,0,09000064868a017f
FDA-2024-N-5381-0006,FDA,FDA-2024-N-5381,Reference 22 Preliminary buprenorphine sublingual tablet pharmacokinetic,Supporting & Related Material,Background Material,2025-01-06T05:00:00Z,2025,1,,,2025-01-06T19:19:13Z,,0,0,09000064868a01ef